Pulp NecrosesPhase 2/3MSCNCT04545307
Transplantation of Allogeneic MSC in Patients With Pulp Necrosis and Chronic Apical Periodontitis
A Phase 2/3 study testing Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis in people with Pulp Necroses and Apical Periodontitis, run by Universidad Central de Venezuela at 1 site in Venezuela.
Trial summary
The purpose of the study is to evaluate the effect of Mesenchymal Stromal Cell (MSC) implantation on pulp and periapical regeneration of immature teeth with pulp necrosis and chronic apical periodontitis. BACKGROUND: Post-traumatic pulp necrosis prevents root development in children and adolescents. Read more about this study
- Who is it for?
- Ages 6 to 16 yearsHealthy volunteers can take part
- Conditions the study is for
- Pulp Necroses, Apical Periodontitis
- What is being tested?
- Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 5 participants
- Where
- 1 siteVenezuela
- Study dates
- 27 Nov 2019to 27 Jan 2020
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 16 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Diagnosis of pulp necrosis and apical periodontitis in teeth with immature apices.
- Informed consent by the patient's representative and consent by the patient to receive bone marrow allogeneic mesenchymal stromal cell transplantation treatment.
Who cannot join
- HIV positive
- Hepatitits B or C positive
- Autoimmune diseases: lupus, rheumatoid arthritis.
- Neoplastic diseases.
- Major metabolic disorders
- Pregnancy
- Being on steroid treatment
- Other criteria that the researchers consider inappropriate for the inclusion of the patient
Trial locations and contacts
1 site in 1 country.
Venezuela1 site
Unidad de Terapia Celular del Instituto de Investigaciones Científicas
San Antonio de Los Altos, Miranda, 1020-A
About this study
Official title: Transplantation of Allogeneic Mesenchymal Stromal Cells in Patients With Immature Apex Teeth With Pulp Necrosis and Chronic Apical Periodontitis
The purpose of the study is to evaluate the effect of Mesenchymal Stromal Cell (MSC) implantation on pulp and periapical regeneration of immature teeth with pulp necrosis and chronic apical periodontitis.
BACKGROUND:
Read more
- Post-traumatic pulp necrosis prevents root development in children and adolescents.
- The multipotent ability of MSC to differentiate into bone-forming cells (osteoblasts) and dentin-forming cells (Odontoblast) has allowed the development of protocols to induce dental pulp regeneration in preclinical models and patients with immature teeth with pulpal necrosis.
IMPACT:
- Worldwide, post-traumatic pulp necrosis in children and adolescents constitutes a health problem in the endodontic area.
- Treatment with MSC would provide an effective therapeutic alternative to patients with pulp necrosis and incomplete root formation.
- The possible pulp and periapical regeneration of immature teeth induced by MSC would have a huge impact on the treatment of these patients.
Eligibility for EMC implant study Age: 6 to 16 years Sex: Male or Female Healthy volunteers accepted: NO.
TREATMENT GROUPS:
In the present study, the implantation of MSC will be performed in patients with immature teeth with pulpal necrosis with apical periodontitis, who will receive the appropriate endodontic treatment (according to the guidelines of the American Association of Endodontics) and implantation of allogeneic BM-MSC . This group will be compared with the history made in the Postgraduate Endodontics of the Universidad Central de Venezuela (UCV) and with international case series made by revascularization.
Clinical follow-up of each patient:
- Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of MSC.
- Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of MSC.
- A tomographic evaluation will be performed when was evident periapical repair in a periapical radiograph. To measure root formation, root canal narrowing and verification the periapical repair in 3D.
Read the detailed description
The endodontic procedure in the patients included in this study will focus on cases of pulp necrosis with apical periodontitis without evidence of infectious processes.
MATERIALS AND METHODS. Reagents Murine monoclonal antibodies, directed against human differentiation antigens (CD34, CD45, CD14, CD90, CD73, CD29, CD49b, CD166), conjugated to fluorescein isothiocyanate (CFI) or phycoerythrin (PE) were purchased from BD Biosciences (USA).
Isolation and culture of mesenchymal stromal cells (MSC) obtained from human bone marrow. In the present study, isolated EMFs from bone marrow (BM) from patients with a diagnosis of post-traumatic nonunion (failure of a bone union at fracture sites) will be used. These cells were transplanted into the pseudoarthrosis site to induce bone regeneration in these patients. The protocol for bone regeneration through EMF transplantation was carried out at the University Hospital of Caracas, Hospital Universitario de Los Andes, Hospital Pérez de León II and has the approval of the Bioethics Committees of each institution and each patient through informed consent. In this protocol, the BM of each patient was isolated by a puncture in the iliac crest. This procedure was performed in the operating room, under anesthesia and by a medical specialist. The MO aspirate was placed in alpha-MEM medium (Invitrogen, USA) with heparin (Sanofi Aventis). The mononuclear cells were separated by centrifugation on a Ficoll-Hypaque gradient (GE Healthcare, Sweden) and cultured in alpha-MEM-Chang medium (Irvine Scientific, USA) enriched with 20% autologous serum. These cells were kept in culture in a controlled environment at 37ºC and 5% CO2. After 72 hours, non-adherent cells were eliminated, and a basal culture medium (alpha-MEM-Chang / 20% autologous serum) was added. Their adherence to the plastic isolated the MSCs. Culture medium exchanges were made until reaching a confluence close to 70-80%. The MSCs were expanded by pealing the cultures, following the process described above. Microbiological examinations were performed after obtaining the BM and before performing the MSC implantation. After using MSC, a batch of these cells were cryopreserved at -70 -C.
Phenotypic characterization of MSC. Phenotypic characterization studies of MSC were carried out by flow cytometry. For which the MO adherent cells were detached from the culture flask by using trypsin-like enzymes. Subsequently, the cells were incubated with antibodies specific for MSC markers (CD90, CD73, CD105, CD29, CD166 and CD49b) and hematopoietic (CD34, CD45 and CD14). Cytometric analysis of the expression markers showed that 100% of the cells used for transplantation in each patient were MSC.
MSC differentiation studies. The multipotential differentiation capacity of MSCs was examined by culturing these cells in osteogenic, chondrogenic and adipogenic differentiation media, following a methodology similar to that previously described. Briefly, the MSCs were detached and seeded in 24-well culture plates at a cell density of 5x104 per well, proceeding to add the corresponding differentiation medium. For osteogenic differentiation, MSCs were cultured in the presence of basal medium enriched with dexamethasone (100nM, Biotech), ascorbic acid (10mM, Sigma), inorganic phosphate (1.8mM, Merck) and beta-glycerol phosphate (2mM, Sigma). For chondrogenic differentiation, cells were cultured in a commercial medium for chondrocytes (Cell Application, USA) and for differentiation towards the adipogenic lineage the commercial medium NH Adipodiff Human (Miltenyi, USA) was used. In all cases, the cells were kept in culture for 21-28 days with medium changes every 4-5 days. To demonstrate the changes associated with the differentiation process, the cells were fixed using paraformaldehyde (Merck, USA) and specific stains were performed for each case. Briefly, alizarin red to detect calcium deposition (evidence of osteogenesis), Alcian blue to detect proteoglycans (evidence of chondrogenesis), and oil red (Oil Red) to see lipids (evidence of adipogenesis). In all cases, microscopic observation and photographic registration were carried out. For endothelial differentiation (CEn), EMFs were cultured in MCDB 131 medium (Invitrogen, USA) enriched with 10% autologous serum, 10µg / ml of human epidermal growth factor (hu-EGF, R\&D) and hydrocortisone (1µg / ml, Sigma).
MSC implantation in patients with pulp necrosis and apical periodontitis. All MSC processing procedures will be carried out in the cleanroom of the IVIC Cell Therapy Unit following the standards of good manufacturing practice (GMP). Allogeneic BM-MSC from patients diagnosed with post-traumatic nonunion and treated with implantation of these cells will be used to induce bone regeneration. The MSC to be used in this protocol have previously been phenotypically and functionally characterized. The MSC will be thawed, grown and expanded as previously described. A part of the cells will be kept in a medium for MSCs, and another part will be cultured in endothelial differentiation medium (CEM-Endo). Once the required number of MSCs and MSCs-Endo have been reached, a suspension of these cells (75,000 cells from each of them) will be placed in sterile culture tubes containing DMEM-F12 culture medium, without phenol red, supplemented with 20% autologous serum. Each tube containing MSC / MSC-Endo will be transported in a small biological sample transport cellar, at room temperature, to the Dentistry Service of the Instituto Venezolano de Investigaciones Científicas (IVIC).
Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the CEM / CEM-Endo "button (pellet)" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the CEM / CEM-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth.
Post-implantation clinical evaluation of EMF
- Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of EMC.
- Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of mesenchymal stromal cells.
- A tomographic evaluation will be performed when the periapical repair will be evident in a periapical radiograph.
- Conditions
- Pulp Necroses, Apical Periodontitis
- Being tested
- Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis
- Keywords
- BM-MSC, Pulp regeneration
- Medical subject headings
- Dental Pulp Necrosis, Periapical Periodontitis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitisBiological
The implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis
| Study group | Role | What they receive |
|---|---|---|
| Allogenic transplant of BM-MSCs | Experimental | Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo "button (pellet)" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth. Receives: Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sings and Symptoms Absence
Through clinical inspection evaluate absence of fistula, intra or extra oral inflammation, no tender to percussion or a palpation
Measured: 15 days post implant
Root canal Narrowing
Through periodical radiographs measure the root canal lumen months after months to evaluate any reduction of the lumen
Measured: 6 to 12 months
Elongation of the root
Through periodical radiographs measure the teeth length from the incisal border to the apex month after month to evaluate any increase of the root length
Measured: 6 to 12 month
Sensitivity tests perception
With the aid of pulpometer and Endo Ice evaluate if the patient start to feel any stimulation
Measured: 6 to 12 months
Repair of the bone lesion produced by the apical periodontitis
Through a periodical radiograph evaluate month after month the increase of radiopacity in the radiolucent area produced by the apical periodontitis. When an evident repair is confirmed a tomography study will be carry out to evaluate it in 3D
Measured: 12 to 24 months
Secondary outcomes (2)
Stability of bio ceramic cements used in the obturation of the access cavity
Through periapical radiographs evaluate the maintenance of the bio ceramic cement in contact with the implant
Measured: 6 to 12 months
Evaluate blood circulation within the root canal
By means of pulse oximeter evaluate the increase of the activity
Measured: 6 to 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2020
- Study start27 Nov 2019
- Primary completion27 Dec 2019
- Study completion27 Jan 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (18)Papers the sponsor has linked to this study.
- Other trials for Pulp NecrosesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- PRP clot loaded of BM-MSC in order to regenerate dental pulp tissue, placed in the root canal of an immature tooth from a patient with pulp necrosis and chronic apical periodontitis
- Masking
- None (open label)
- Enrolment
- 5 participants (actual)
Sponsor and investigators
- Lead sponsor
- Universidad Central de Venezuela
- Sponsor type
- University, hospital or other
- Collaborators
- Instituto Venezolano de Investigaciones Cientificas
- Responsible party
- Principal investigator, Jose Francisco Gomez-Sosa, Instituto Venezolano de Investigaciones Cientificas
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04545307
- Sponsor's protocol ID
- MSCYPPNAP001
- Acronym
- MSC
- Status last verified
- Sep 2020
- First submitted
- 3 Sep 2020
- Last updated
- 16 Sep 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Possibly we can share the individual clinical, radiograph and tomographic outcome of every patient enrolled in the study, mainly focus on the difficulty that every patient present.
Publications
Antunes LS, Salles AG, Gomes CC, Andrade TB, Delmindo MP, Antunes LA. The effectiveness of pulp revascularization in root formation of necrotic immature permanent teeth: A systematic review. Acta Odontol Scand. 2016;74(3):161-9. doi: 10.3109/00016357.2015.1069394. Epub 2015 Jul 15.
PubMed 26179397Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006 Aug 1;98(5):1076-84. doi: 10.1002/jcb.20886.
PubMed 16619257Diaz-Solano D, Wittig O, Mota JD, Cardier JE. Isolation and Characterization of Multipotential Mesenchymal Stromal Cells from Congenital Pseudoarthrosis of the Tibia: Case Report. Anat Rec (Hoboken). 2015 Oct;298(10):1804-14. doi: 10.1002/ar.23198. Epub 2015 Jul 30.
PubMed 26194170Eramo S, Natali A, Pinna R, Milia E. Dental pulp regeneration via cell homing. Int Endod J. 2018 Apr;51(4):405-419. doi: 10.1111/iej.12868. Epub 2017 Nov 7.
PubMed 29047120Fouad AF. Microbiological aspects of traumatic injuries. Dent Traumatol. 2019 Dec;35(6):324-332. doi: 10.1111/edt.12494. Epub 2019 Oct 14.
PubMed 31125490Guerrero F, Mendoza A, Ribas D, Aspiazu K. Apexification: A systematic review. J Conserv Dent. 2018 Sep-Oct;21(5):462-465. doi: 10.4103/JCD.JCD_96_18.
PubMed 30294103Hawryluk GW, Mothe A, Wang J, Wang S, Tator C, Fehlings MG. An in vivo characterization of trophic factor production following neural precursor cell or bone marrow stromal cell transplantation for spinal cord injury. Stem Cells Dev. 2012 Aug 10;21(12):2222-38. doi: 10.1089/scd.2011.0596. Epub 2012 Feb 7.
PubMed 22085254Huang GT. Dental pulp and dentin tissue engineering and regeneration: advancement and challenge. Front Biosci (Elite Ed). 2011 Jan 1;3(2):788-800. doi: 10.2741/e286.
PubMed 21196351Iohara K, Nakashima M, Ito M, Ishikawa M, Nakasima A, Akamine A. Dentin regeneration by dental pulp stem cell therapy with recombinant human bone morphogenetic protein 2. J Dent Res. 2004 Aug;83(8):590-5. doi: 10.1177/154405910408300802.
PubMed 15271965Moradi S, Talati A, Forghani M, Jafarian AH, Naseri M, Shojaeian S. Immunohistological Evaluation of Revascularized Immature Permanent Necrotic Teeth Treated by Platelet-Rich Plasma: An Animal Investigation. Cell J. 2016 Fall;18(3):389-96. doi: 10.22074/cellj.2016.4567. Epub 2016 Aug 24.
PubMed 27602321Murakami M, Hayashi Y, Iohara K, Osako Y, Hirose Y, Nakashima M. Trophic Effects and Regenerative Potential of Mobilized Mesenchymal Stem Cells From Bone Marrow and Adipose Tissue as Alternative Cell Sources for Pulp/Dentin Regeneration. Cell Transplant. 2015;24(9):1753-65. doi: 10.3727/096368914X683502. Epub 2014 Jul 30.
PubMed 25199044Nakashima M, Iohara K. Regeneration of dental pulp by stem cells. Adv Dent Res. 2011 Jul;23(3):313-9. doi: 10.1177/0022034511405323.
PubMed 21677085Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999 Apr 2;284(5411):143-7. doi: 10.1126/science.284.5411.143.
PubMed 10102814Shammaa R, El-Kadiry AE, Abusarah J, Rafei M. Mesenchymal Stem Cells Beyond Regenerative Medicine. Front Cell Dev Biol. 2020 Feb 18;8:72. doi: 10.3389/fcell.2020.00072. eCollection 2020.
PubMed 32133358Wang X, Thibodeau B, Trope M, Lin LM, Huang GT. Histologic characterization of regenerated tissues in canal space after the revitalization/revascularization procedure of immature dog teeth with apical periodontitis. J Endod. 2010 Jan;36(1):56-63. doi: 10.1016/j.joen.2009.09.039.
PubMed 20003936
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Transplantation of Allogeneic Mesenchymal Stromal Cells in Patients With Immature Apex Teeth With Pulp Necrosis and Chronic Apical Periodontitis
- ClinicalTrials.gov ID
- NCT04545307
- Acronym / sponsor ID
- MSC / MSCYPPNAP001
- Conditions
- Pulp Necroses, Apical Periodontitis
- Keywords
- BM-MSC, Pulp regeneration
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 5 participants (actual)
- Lead sponsor
- Universidad Central de VenezuelaUniversity, hospital or other
- Collaborators
- Instituto Venezolano de Investigaciones Cientificas
- Study start
- 27 Nov 2019 (actual)
- Primary completion
- 27 Dec 2019 (actual)
- Study completion
- 27 Jan 2020 (actual)
- First posted
- 11 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to evaluate the effect of Mesenchymal Stromal Cell (MSC) implantation on pulp and periapical regeneration of immature teeth with pulp necrosis and chronic apical periodontitis.
BACKGROUND:
- Post-traumatic pulp necrosis prevents root development in children and adolescents.
- The multipotent ability of MSC to differentiate into bone-forming cells (osteoblasts) and dentin-forming cells (Odontoblast) has allowed the development of protocols to induce dental pulp regeneration in preclinical models and patients with immature teeth with pulpal necrosis.
IMPACT:
- Worldwide, post-traumatic pulp necrosis in children and adolescents constitutes a health problem in the endodontic area.
- Treatment with MSC would provide an effective therapeutic alternative to patients with pulp necrosis and incomplete root formation.
- The possible pulp and periapical regeneration of immature teeth induced by MSC would have a huge impact on the treatment of these patients.
Eligibility for EMC implant study Age: 6 to 16 years Sex: Male or Female Healthy volunteers accepted: NO.
TREATMENT GROUPS:
In the present study, the implantation of MSC will be performed in patients with immature teeth with pulpal necrosis with apical periodontitis, who will receive the appropriate endodontic treatment (according to the guidelines of the American Association of Endodontics) and implantation of allogeneic BM-MSC . This group will be compared with the history made in the Postgraduate Endodontics of the Universidad Central de Venezuela (UCV) and with international case series made by revascularization.
Clinical follow-up of each patient:
- Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of MSC.
- Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of MSC.
- A tomographic evaluation will be performed when was evident periapical repair in a periapical radiograph. To measure root formation, root canal narrowing and verification the periapical repair in 3D.
Detailed description
The endodontic procedure in the patients included in this study will focus on cases of pulp necrosis with apical periodontitis without evidence of infectious processes.
MATERIALS AND METHODS. Reagents Murine monoclonal antibodies, directed against human differentiation antigens (CD34, CD45, CD14, CD90, CD73, CD29, CD49b, CD166), conjugated to fluorescein isothiocyanate (CFI) or phycoerythrin (PE) were purchased from BD Biosciences (USA).
Isolation and culture of mesenchymal stromal cells (MSC) obtained from human bone marrow. In the present study, isolated EMFs from bone marrow (BM) from patients with a diagnosis of post-traumatic nonunion (failure of a bone union at fracture sites) will be used. These cells were transplanted into the pseudoarthrosis site to induce bone regeneration in these patients. The protocol for bone regeneration through EMF transplantation was carried out at the University Hospital of Caracas, Hospital Universitario de Los Andes, Hospital Pérez de León II and has the approval of the Bioethics Committees of each institution and each patient through informed consent. In this protocol, the BM of each patient was isolated by a puncture in the iliac crest. This procedure was performed in the operating room, under anesthesia and by a medical specialist. The MO aspirate was placed in alpha-MEM medium (Invitrogen, USA) with heparin (Sanofi Aventis). The mononuclear cells were separated by centrifugation on a Ficoll-Hypaque gradient (GE Healthcare, Sweden) and cultured in alpha-MEM-Chang medium (Irvine Scientific, USA) enriched with 20% autologous serum. These cells were kept in culture in a controlled environment at 37ºC and 5% CO2. After 72 hours, non-adherent cells were eliminated, and a basal culture medium (alpha-MEM-Chang / 20% autologous serum) was added. Their adherence to the plastic isolated the MSCs. Culture medium exchanges were made until reaching a confluence close to 70-80%. The MSCs were expanded by pealing the cultures, following the process described above. Microbiological examinations were performed after obtaining the BM and before performing the MSC implantation. After using MSC, a batch of these cells were cryopreserved at -70 -C.
Phenotypic characterization of MSC. Phenotypic characterization studies of MSC were carried out by flow cytometry. For which the MO adherent cells were detached from the culture flask by using trypsin-like enzymes. Subsequently, the cells were incubated with antibodies specific for MSC markers (CD90, CD73, CD105, CD29, CD166 and CD49b) and hematopoietic (CD34, CD45 and CD14). Cytometric analysis of the expression markers showed that 100% of the cells used for transplantation in each patient were MSC.
MSC differentiation studies. The multipotential differentiation capacity of MSCs was examined by culturing these cells in osteogenic, chondrogenic and adipogenic differentiation media, following a methodology similar to that previously described. Briefly, the MSCs were detached and seeded in 24-well culture plates at a cell density of 5x104 per well, proceeding to add the corresponding differentiation medium. For osteogenic differentiation, MSCs were cultured in the presence of basal medium enriched with dexamethasone (100nM, Biotech), ascorbic acid (10mM, Sigma), inorganic phosphate (1.8mM, Merck) and beta-glycerol phosphate (2mM, Sigma). For chondrogenic differentiation, cells were cultured in a commercial medium for chondrocytes (Cell Application, USA) and for differentiation towards the adipogenic lineage the commercial medium NH Adipodiff Human (Miltenyi, USA) was used. In all cases, the cells were kept in culture for 21-28 days with medium changes every 4-5 days. To demonstrate the changes associated with the differentiation process, the cells were fixed using paraformaldehyde (Merck, USA) and specific stains were performed for each case. Briefly, alizarin red to detect calcium deposition (evidence of osteogenesis), Alcian blue to detect proteoglycans (evidence of chondrogenesis), and oil red (Oil Red) to see lipids (evidence of adipogenesis). In all cases, microscopic observation and photographic registration were carried out. For endothelial differentiation (CEn), EMFs were cultured in MCDB 131 medium (Invitrogen, USA) enriched with 10% autologous serum, 10µg / ml of human epidermal growth factor (hu-EGF, R\&D) and hydrocortisone (1µg / ml, Sigma).
MSC implantation in patients with pulp necrosis and apical periodontitis. All MSC processing procedures will be carried out in the cleanroom of the IVIC Cell Therapy Unit following the standards of good manufacturing practice (GMP). Allogeneic BM-MSC from patients diagnosed with post-traumatic nonunion and treated with implantation of these cells will be used to induce bone regeneration. The MSC to be used in this protocol have previously been phenotypically and functionally characterized. The MSC will be thawed, grown and expanded as previously described. A part of the cells will be kept in a medium for MSCs, and another part will be cultured in endothelial differentiation medium (CEM-Endo). Once the required number of MSCs and MSCs-Endo have been reached, a suspension of these cells (75,000 cells from each of them) will be placed in sterile culture tubes containing DMEM-F12 culture medium, without phenol red, supplemented with 20% autologous serum. Each tube containing MSC / MSC-Endo will be transported in a small biological sample transport cellar, at room temperature, to the Dentistry Service of the Instituto Venezolano de Investigaciones Científicas (IVIC).
Under sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the CEM / CEM-Endo "button (pellet)" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the CEM / CEM-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth.
Post-implantation clinical evaluation of EMF
- Clinical controls (facial evaluation, gingival evaluation, apical palpation, horizontal and vertical percussion, cold and heat sensitivity tests) will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, a clinical evaluation will be carried out at the two years post-implantation of EMC.
- Radiological controls will be carried out on days 0, 7, 30, 90, 180 and 364. Additionally, they will be carried out two years post-implantation of mesenchymal stromal cells.
- A tomographic evaluation will be performed when the periapical repair will be evident in a periapical radiograph.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- PRP clot loaded of BM-MSC in order to regenerate dental pulp tissue, placed in the root canal of an immature tooth from a patient with pulp necrosis and chronic apical periodontitis
| Arm | Type | Receives |
|---|---|---|
| Allogenic transplant of BM-MSCs | Experimental | Biological: Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitisUnder sterile conditions, the patient will be locally anesthetized in the affected tooth area; the root canal of the affected tooth will be exposed and prepared to perform the MSC / MSC-Endo / PRP implant. At the same time, the culture medium supernatant is removed from each tube and the MSC / MSC-Endo "button (pellet)" is resuspended in autologous platelet-rich plasma (PRP). Subsequently to the MSC / MSC-Endo / PRP suspension, 5% CaCl2 and thrombin will be added. Immediately, and before the clot forms, 20 microliters of the MSC / MSC-Endo / PRP suspension will be placed in the root canal, covered with a collagen membrane. Subsequently, the obturation procedure with bioceramics will be carried out at the level of the pulp chamber, ionomeric glass to protect the bioceramic and later composite resin to restore the tooth. |
Who may qualify
- Ages
- 6 to 16 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (2 listed)
- Diagnosis of pulp necrosis and apical periodontitis in teeth with immature apices.
- Informed consent by the patient's representative and consent by the patient to receive bone marrow allogeneic mesenchymal stromal cell transplantation treatment.
Key exclusion criteria (8 listed)
- HIV positive
- Hepatitits B or C positive
- Autoimmune diseases: lupus, rheumatoid arthritis.
- Neoplastic diseases.
- Major metabolic disorders
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitisThe implant of BM-MSC/MSC-Endo/PRP in a clean and shaped root canal from patients with immature apexes and pulpal necroses and apical periodontitis | Biological | Allogenic transplant of BM-MSCs |
Primary outcome
Sings and Symptoms Absence
Time frame: 15 days post implant
Through clinical inspection evaluate absence of fistula, intra or extra oral inflammation, no tender to percussion or a palpation
Root canal Narrowing
Time frame: 6 to 12 months
Through periodical radiographs measure the root canal lumen months after months to evaluate any reduction of the lumen
Elongation of the root
Time frame: 6 to 12 month
Through periodical radiographs measure the teeth length from the incisal border to the apex month after month to evaluate any increase of the root length
Sensitivity tests perception
Time frame: 6 to 12 months
With the aid of pulpometer and Endo Ice evaluate if the patient start to feel any stimulation
Repair of the bone lesion produced by the apical periodontitis
Time frame: 12 to 24 months
Through a periodical radiograph evaluate month after month the increase of radiopacity in the radiolucent area produced by the apical periodontitis. When an evident repair is confirmed a tomography study will be carry out to evaluate it in 3D
2 secondary outcomes
Stability of bio ceramic cements used in the obturation of the access cavity
Time frame: 6 to 12 months
Evaluate blood circulation within the root canal
Time frame: 6 to 24 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2020.
- Background: PubMed 26179397Antunes LS, Salles AG, Gomes CC, Andrade TB, Delmindo MP, Antunes LA. The effectiveness of pulp revascularization in root formation of necrotic immature permanent teeth: A systematic review. Acta Odontol Scand. 2016;74(3):161-9. doi: 10.3109/00016357.2015.1069394. Epub 2015 Jul 15.
- Background: PubMed 16619257Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006 Aug 1;98(5):1076-84. doi: 10.1002/jcb.20886.
- Background: PubMed 26194170Diaz-Solano D, Wittig O, Mota JD, Cardier JE. Isolation and Characterization of Multipotential Mesenchymal Stromal Cells from Congenital Pseudoarthrosis of the Tibia: Case Report. Anat Rec (Hoboken). 2015 Oct;298(10):1804-14. doi: 10.1002/ar.23198. Epub 2015 Jul 30.
- Background: PubMed 29047120Eramo S, Natali A, Pinna R, Milia E. Dental pulp regeneration via cell homing. Int Endod J. 2018 Apr;51(4):405-419. doi: 10.1111/iej.12868. Epub 2017 Nov 7.
- Background: PubMed 31125490Fouad AF. Microbiological aspects of traumatic injuries. Dent Traumatol. 2019 Dec;35(6):324-332. doi: 10.1111/edt.12494. Epub 2019 Oct 14.
- Background: PubMed 30294103Guerrero F, Mendoza A, Ribas D, Aspiazu K. Apexification: A systematic review. J Conserv Dent. 2018 Sep-Oct;21(5):462-465. doi: 10.4103/JCD.JCD_96_18.
- Background: PubMed 22085254Hawryluk GW, Mothe A, Wang J, Wang S, Tator C, Fehlings MG. An in vivo characterization of trophic factor production following neural precursor cell or bone marrow stromal cell transplantation for spinal cord injury. Stem Cells Dev. 2012 Aug 10;21(12):2222-38. doi: 10.1089/scd.2011.0596. Epub 2012 Feb 7.
- Background: PubMed 21196351Huang GT. Dental pulp and dentin tissue engineering and regeneration: advancement and challenge. Front Biosci (Elite Ed). 2011 Jan 1;3(2):788-800. doi: 10.2741/e286.
- Background: PubMed 15271965Iohara K, Nakashima M, Ito M, Ishikawa M, Nakasima A, Akamine A. Dentin regeneration by dental pulp stem cell therapy with recombinant human bone morphogenetic protein 2. J Dent Res. 2004 Aug;83(8):590-5. doi: 10.1177/154405910408300802.
- Background: PubMed 27602321Moradi S, Talati A, Forghani M, Jafarian AH, Naseri M, Shojaeian S. Immunohistological Evaluation of Revascularized Immature Permanent Necrotic Teeth Treated by Platelet-Rich Plasma: An Animal Investigation. Cell J. 2016 Fall;18(3):389-96. doi: 10.22074/cellj.2016.4567. Epub 2016 Aug 24.
- Background: PubMed 25199044Murakami M, Hayashi Y, Iohara K, Osako Y, Hirose Y, Nakashima M. Trophic Effects and Regenerative Potential of Mobilized Mesenchymal Stem Cells From Bone Marrow and Adipose Tissue as Alternative Cell Sources for Pulp/Dentin Regeneration. Cell Transplant. 2015;24(9):1753-65. doi: 10.3727/096368914X683502. Epub 2014 Jul 30.
- Background: PubMed 21677085Nakashima M, Iohara K. Regeneration of dental pulp by stem cells. Adv Dent Res. 2011 Jul;23(3):313-9. doi: 10.1177/0022034511405323.
- Individual participant dataSharing planned: Undecided. Possibly we can share the individual clinical, radiograph and tomographic outcome of every patient enrolled in the study, mainly focus on the difficulty that every patient present.
Related trials for Pulp Necroses
Not yet recruiting
Post-operative Pain and Clinical Outcome After Single-cone Obturation With a Calcium Silicate-based Versus Epoxy Resin Sealer
Post Operative Pain, Acute, Irreversible Pulpitis (Toothache)
Not yet recruiting
PRP-Assisted Regenerative Endodontics Versus Conventional Root Canal Treatment in Mature Necrotic Teeth
Pulp Necrosis, Apical Periodontitis
Not yet recruiting
Clinical and Inflammatory Outcomes of Regenerative Endodontic Treatment Using Injectable Platelet-Rich Fibrin in Mature Necrotic Teeth With Chronic Apical Periodontitis.
Chronic Apical Periodontitis, Pulp Necrosis
Recruiting
Conventional and Nano-Metronidazole Irrigation With/Without Activation in Necrotic Teeth With Apical Periodontitis
Pulp Necrosis, Apical Periodontitis
Not yet recruiting
The Effect of Bitewing Radiography on Outcomes and Costs of Treating Caries in Permanent Teeth
Dental Caries, Teeth Loss
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Allogenic transplant of BM-MSC in a root canal from patients with immature apexes and pulpar necrosis and apical periodontitis in people with Pulp Necroses and Apical Periodontitis, run by Universidad Central de Venezuela at 1 site in Venezuela.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Sep 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Venezuela. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sings and Symptoms Absence (time frame: 15 days post implant). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04545307, which also lists 18 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2020.